UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

Alimentary pharmacology & therapeutics, 2012-12, Vol.36 (11-12), p.1040-1048

2012

Volltextzugriff (PDF)

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease

Alimentary pharmacology & therapeutics, 2004-03, Vol.19 (5), p.511-519

2004

Volltextzugriff (PDF)

Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease

Gut, 2001-12, Vol.49 (6), p.777-782

2001

Volltextzugriff (PDF)

An insertion–deletion polymorphism in the Interferon Regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases

Human molecular genetics, 2007-12, Vol.16 (24), p.3008-3016

2007

Volltextzugriff (PDF)

Long-term evolution and predictive factors of mild inflammatory bowel disease

Scandinavian journal of gastroenterology, 2016-06, Vol.51 (6), p.712-719

2016

Volltextzugriff (PDF)

Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype

Gut, 2003-04, Vol.52 (4), p.552-557

2003

Volltextzugriff (PDF)

The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases

Genes and immunity, 2007-07, Vol.8 (5), p.387-397

2007

Volltextzugriff (PDF)

A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism

Scandinavian journal of gastroenterology, 2002-07, Vol.37 (7), p.818-824

2002

Volltextzugriff (PDF)

Are we giving biologics too much time？ When should we stop treatment

World journal of gastroenterology : WJG, 2008-09, Vol.14 (36), p.5528-5531

2008

Volltextzugriff (PDF)

Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids

Journal of Crohn's and colitis, 2011-06, Vol.5 (3), p.196-202

2011

Volltextzugriff (PDF)

Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease

Alimentary pharmacology & therapeutics, 2004-09, Vol.20 (6), p.607-614

2004

Volltextzugriff (PDF)

Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply

Alimentary pharmacology & therapeutics, 2013-04, Vol.37 (7), p.752-753

2013

Volltextzugriff (PDF)

Should patients under long‐term anti‐TNF therapies be followed for tuberculosis contamination?

Inflammatory bowel diseases, 2010-08, Vol.16 (8), p.1271-1272

2010

Volltextzugriff (PDF)

Increased production of matrix metalloproteinase‐3 and tissue inhibitor of metalloproteinase‐1 by inflamed mucosa in inflammatory bowel disease

Clinical and experimental immunology, 2000-05, Vol.120 (2), p.241-246

2000

Volltextzugriff (PDF)

Profile of soluble cytokine receptors in Crohn’s disease

Gut, 2005-04, Vol.54 (4), p.488-495

2005

Volltextzugriff (PDF)

Revue de l'épidémiologie de la maladie de Crohn en Europe

Acta endoscopica, 2003-04, Vol.33 (2), p.199-205

2003

Volltextzugriff (PDF)

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease

The American journal of gastroenterology, 2002-06, Vol.97 (6), p.1458-1462

2002

Volltextzugriff (PDF)

Therapeutic Drug Monitoring of Azathioprine and 6-Mercaptopurine Metabolites in Crohn Disease

Scandinavian journal of gastroenterology, 2001-01, Vol.36 (1), p.71-76

2001

Volltextzugriff (PDF)

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease

The American journal of gastroenterology, 2002, Vol.97 (6), p.1458-1462

2002

Volltextzugriff (PDF)

Increased expression of receptor activator of NF‐κB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients

Clinical and experimental immunology, 2004-12, Vol.138 (3), p.491-498

2004

Volltextzugriff (PDF)

Azathioprine Withdrawal in Patients With Crohn's Disease Maintained on Prolonged Remission: A High Risk of Relapse

Clinical gastroenterology and hepatology, 2009, Vol.7 (1), p.80-85

2009

Volltextzugriff (PDF)

Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission

International journal of colorectal disease, 2000-08, Vol.15 (4), p.206-210

2000

Volltextzugriff (PDF)

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

Gastroenterology (New York, N.Y. 1943), 2012, Vol.142 (1), p.63-70.e5

2012

Volltextzugriff (PDF)

Données épidémiologiques

Acta endoscopica, 2005-10, Vol.35 (5), p.751-752

Belaiche, J.

2005

Volltextzugriff (PDF)

Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine

Alimentary pharmacology & therapeutics, 2003-08, Vol.18 (4), p.401-408

2003

Volltextzugriff (PDF)

1 – 25 von 385

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(325)
Mit Volltextzugriff
(209)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(242)
Science & Technology
(150)
Life Sciences & Biomedicine
(143)
Male
(134)
Female
(122)
Gastroenterology & Hepatology
(121)
Adult
(114)
Middle Aged
(104)
Human Health Sciences
(95)
Sciences De La Santé Humaine
(95)
Biological And Medical Sciences
(92)
Medical Sciences
(87)
Gastroentérologie & Hépatologie
(84)
Aged
(60)
Gastroenterology. Liver. Pancreas. Abdomen
(49)
Other Diseases. Semiology
(43)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(40)
Crohn's Disease
(36)
Adolescent
(35)
Crohn Disease - Drug Therapy
(31)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease

Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease

An insertion–deletion polymorphism in the Interferon Regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases

Long-term evolution and predictive factors of mild inflammatory bowel disease

Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype

The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases

A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism

Are we giving biologics too much time？ When should we stop treatment

Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids

Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease

Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply

Should patients under long‐term anti‐TNF therapies be followed for tuberculosis contamination?

Increased production of matrix metalloproteinase‐3 and tissue inhibitor of metalloproteinase‐1 by inflamed mucosa in inflammatory bowel disease

Profile of soluble cytokine receptors in Crohn’s disease

Revue de l'épidémiologie de la maladie de Crohn en Europe

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease

Therapeutic Drug Monitoring of Azathioprine and 6-Mercaptopurine Metabolites in Crohn Disease

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease

Increased expression of receptor activator of NF‐κB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients

Azathioprine Withdrawal in Patients With Crohn's Disease Maintained on Prolonged Remission: A High Risk of Relapse

Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

Données épidémiologiques

Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine

Suchergebnisse filtern